Monogram Applied sciences mentioned its applied sciences mix 3D printing, superior machine imaginative and prescient, AI, and next-generation robotics. | Supply: Monogram Applied sciences
Zimmer Biomet Holdings, Inc. at the moment introduced that it’s buying Monogram Applied sciences Inc., an orthopedic robotics firm. The worldwide medical expertise developer will purchase all excellent shares of Monogram for $4.04 a share, totaling an fairness worth of $177 million and an enterprise worth of $168 million.
“Monogram’s expertise is a significant leap ahead, demonstrating our dedication to changing into the boldest and broadest innovator in surgical robotics and navigation,” mentioned Ivan Tornos, the chairman, president, and CEO of Zimmer Biomet. “Upon closing, our customer-centric portfolio will encompass essentially the most complete and versatile expertise ecosystem to help the various preferences of an enormous array of surgeons — now and into the long run.”
“With Monogram’s proprietary expertise, Zimmer Biomet has the potential to develop into the primary firm to ship absolutely autonomous capabilities and redefine each the usual of care and the way forward for orthopedic surgical procedure,” he continued.
The respective boards of administrators of Zimmer Biomet and Monogram unanimously authorized the proposed transaction. Zimmer Biomet, which has workplaces in Montpelier, France, and Warsaw, Ind., affords its flagship ROSA platform. ROSA, which lately expanded into shoulder substitute, has 4 purposes, together with the knee.
Zimmer Biomet to include Monogram tech into ROSA
Zimmer Biomet mentioned it expects Monogram Applied sciences’ semi- and absolutely autonomous robotic applied sciences so as to add new and differentiated capabilities to increase its personal surgical robotic.
Monogram has developed a CT-based, semi-autonomous, AI-navigated whole knee arthroplasty (TKA) robotic expertise. It earned FDA 510(ok) clearance in March 2025. The Austin, Texas-based firm mentioned it expects to commercialize the mBôs expertise with Zimmer Biomet implants in early 2027.
As well as, Monogram is creating a completely autonomous model of the mBôs system. It asserted that the expertise might considerably enhance security, effectivity, and outcomes, in addition to handle purposes past TKA.
“Since our inception, we’ve been singularly centered on advancing orthopedic robotics with expertise designed to soundly, effectively, and precisely help surgeons with whole knee arthroplasty,” mentioned Benjamin Sexson, CEO of Monogram. “We’re thrilled by the chance so as to add our expertise to Zimmer Biomet’s main portfolio of surgical robotics, navigation options, and trusted implants and to profit from their deep trade experience and international scale.”
Zimmer Biomet mentioned it expects the acquisition to contribute to income progress in 2027 and past. The firm famous that mBôs will support robotic knee adoption within the U.S., enhance its market share with a broader product vary, and increase its international knee choices.
Zimmer Biomet to increase ROSA purposes
The proposed transaction expands Zimmer Biomet’s intensive suite of orthopedic robotics. This provides it entry to programs and analytics to deal with the wants of surgeons pre-, intra-, and post-operatively. The corporate mentioned its portfolio contains:
- Imageless robotics by its ROSA platform
- A licensed CT-based handheld robotic
- Combined actuality navigation
- AI-based surgical navigation
- A pathway to superior semi- and absolutely autonomous robotics capabilities.
Zimmer Biomet predicted that it is going to be in a position to handle the varied preferences of surgeons globally and a number of types of surgical methods. This contains CT and non-CT, robotic and non-robotic, and guide, surgeon-centered strategies, or semi- or absolutely autonomous applied sciences.
The ROSA platform is quickly approaching 2,000 installations worldwide, the corporate claimed. Zimmer Biomet mentioned it’s dedicated to persevering with to advance the ROSA platform and is investing in a strong R&D pipeline that includes a number of new merchandise and software program purposes anticipated between now and 2027.
This contains ROSA Knee with OptimiZe, which has been submitted to the FDA, and 510(ok) clearance is anticipated later this yr, in addition to ROSA Posterior Hip and the total industrial launch of ROSA Shoulder. Zimmer Biomet has additionally labored with THINK Surgical Inc. on integrating the Persona system with the TMINI surgical robotic.
